Alle Studien
RekrutierungPhase I und Phase II (Integriert) - Erste Verabreichung an MenschenInterventionell

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AZD2962, an IRAK4 inhibitor, as Monotherapy and in Combination with other Agents, in Participants with Hematologic Neoplasms

This early-stage clinical trial is looking at an experimental drug called AZD2962 for adults with specific blood and bone marrow disorders, including myelodysplastic syndromes (MDS) and dysplastic chronic myelomonocytic leukaemia (CMML). In these conditions, the bone marrow struggles to make enough healthy blood cells. Because this is one of the first studies testing AZD2962 in people, the main goal is to check how safe it is and find the most suitable dose. Doctors will closely track any side effects and see how the body breaks down the medicine. They will also look for early signs that AZD2962 can slow down the disease or improve blood counts, either given on its own or with other therapies. Participants will have regular check-ups at a hospital clinic, including blood tests and heart scans, to keep a close eye on their health.

Auf einen Blick

Status
Rekrutierung
Phase
Phase I und Phase II (Integriert) - Erste Verabreichung an Menschen
Sponsor
AstraZeneca AB
Einschreibeziel
7
Starten
11. Aug 2025

Worum geht es in dieser Studie?

Bone marrow is the spongy centre inside our bones where blood cells are made. In conditions like myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), the bone marrow produces abnormal, faulty blood cells. Over time, this can lead to low blood counts, tiredness, frequent infections, or easy bruising, and may sometimes develop into more aggressive forms of blood cancer.

AZD2962 is an experimental medicine known as an IRAK4 inhibitor. It works by blocking a specific protein signal inside cells that can cause inflammation and encourage abnormal blood cells to survive and multiply. By targeting this pathway, scientists hope the drug might slow down or stop the progression of these blood conditions.

This study is an early-phase trial, meaning it is one of the first times AZD2962 is being tested in humans. The researchers want to learn what dose is safe, what side effects might happen, and how long the medicine stays in the bloodstream. They will also check whether the drug helps patients feel better or reduces abnormal cells, whether taken alone or combined with other existing treatments.

Research like this is vital because current treatment choices for MDS and CMML can be limited. Finding new and well-tolerated options could help improve quality of life and provide better long-term control of these diseases in the future.

Wichtige Erkenntnisse

  • Tests a new targeted drug called AZD2962 for MDS and CMML blood disorders.
  • Early-stage trial focused primarily on safety, dosing, and tolerability.
  • Requires regular clinic visits for blood tests, heart checks, and health reviews.
  • Open to adults aged 18 and older who meet specific health criteria.
  • Participation is voluntary, and you can leave the study at any time.

Wer könnte berechtigt sein?

This study is open to adults aged 18 and over who have been diagnosed with specific blood or bone marrow conditions, primarily myelodysplastic syndromes (MDS) or dysplastic chronic myelomonocytic leukaemia (CMML).

To take part, participants generally need to be well enough to manage day-to-day activities and attend regular hospital appointments. Their vital organs, such as the liver, kidneys, and heart, must be working well enough to safely handle a new medication.

People may not be able to join if they have certain serious active infections, unstable heart problems, or if they are pregnant or breastfeeding. The study doctor will review each person's full medical history and recent blood results to confirm whether the trial is a safe and suitable option for them.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am aged 18 or older.
  2. I have been diagnosed with MDS, CMML, or a related blood disorder.
  3. I am well enough to attend regular hospital appointments.
  4. I do not have an uncontrolled, severe infection or major heart problem.
  5. I am willing to undergo regular blood tests and health checks.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you take part, you will receive the study drug AZD2962 either by itself or alongside another medication. You will need to attend regular clinic visits at the trial hospital, especially during the first few weeks when doctors need to watch closely for any side effects.

At your visits, the team will perform routine health checks. These include physical examinations, measuring your blood pressure and temperature, taking regular blood samples, and checking your heart with an electrocardiogram (ECG). You may also have occasional bone marrow tests to see how the disease is responding.

The trial is divided into treatment cycles, and you may continue taking the medicine for as long as it is helping and not causing troublesome side effects. After finishing the medication, the medical team will keep in touch for a follow-up period to check on your overall health.

Potenzielle Risiken und Vorteile

Because AZD2962 is in the early stages of testing, there is a risk of unexpected side effects or reactions that doctors do not yet fully understand. You will also need to spend time attending frequent clinic visits and having tests. On the other hand, the treatment might help manage your blood condition, and the extra medical monitoring means your health will be checked very carefully. Taking part also helps doctors discover new ways to treat blood disorders in the future. Joining the study is completely your choice, and you can change your mind and leave at any point without it affecting your normal NHS care.

Standorte (1)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Spanien

Häufige Fragen

Was ist der Hauptzweck dieser Studie?

The main goal is to find out if the new drug AZD2962 is safe, what dose works best, and whether it shows early signs of helping people with certain blood conditions.

What does 'first-in-human' mean?

It means this is one of the very first clinical trials where this specific drug is being given to people, which is why safety is monitored so closely.

Will I have to pay for the study treatment?

No, clinical trial medicines and study-related tests are provided free of charge, and travel expenses are often covered.

Can I carry on with my normal daily routine?

Most people can continue their usual activities, but you will need to plan for regular hospital visits and let your study team know if you feel unwell or tired.

Kann ich aufhören teilzunehmen, wenn ich meine Meinung ändere?

Yes, taking part is entirely voluntary. You can leave the trial at any time for any reason, and your regular medical team will continue to look after you.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Modular Phase I/II, Open-label, Multicentre Study to Evalu… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.